The separation of ipratropium bromide and its related compounds

Ipratropium bromide, the active component in ipratropium bromide metered dose inhalers (MDI), is used as a bronchodilator for the maintenance and treatment of bronchospasms associated with chronic obstructive pulmonary disease (COPD). The separation of ipratropium bromide, tropic acid, N-isopropyl-nor-atropine (NINA), 8-s ipratropium bromide, apo-ipratropium bromide and the excipients found in the formulation is important for analyzing raw materials and stability samples. We now report a reversed-phase HPLC method that can be used for separating ipratropium bromide and its related compounds, using an acetonitrile/potassium phosphate buffer (100 mM, pH 4.0) gradient mobile phase. Previous methods used for separating ipratropium bromide from its related compounds involved reversed-phase ion-pairing HPLC with UV detection. These methods exhibited less reproducibility, less ruggedness and required a high flow rate. The reported method is linear from 10 to 1000 μg ml −1 with a limit of detection of 60 ng ml −1. In addition, analysis of samples subjected to accelerated stability conditions showed that all degradants are resolved from the active component, resulting in a stability-indicating assay. This assay also saved mobile phase and eliminated problems associated with ion-pairing reagents.